Kindred Biosciences, Inc. (NASDAQ: KIN) Starts Presentation at LD Micro 2017 Invitational
Kindred Biosciences (NASDAQ: KIN) is a development-stage biopharmaceutical company that focuses on the development of therapies for pets. The company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. Its lead product candidates include Zimeta, a dipyrone injection for the control of pyrexia (fever) in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats. The company's other small molecule product candidates consist of KIND-014 for the treatment of equine gastric ulcers in horses; and KIND-015 for the management of clinical signs associated with equine metabolic…